ArticleNew microbes and new infections2025

An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.

Isabel H Gonzalez-Bocco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.